Arcutis Biotherapeutics, Inc. (ARQT)
24.78
-0.30
(-1.20%)
USD |
NASDAQ |
Aug 24, 16:00
24.79
+0.01
(+0.04%)
After-Hours: 20:00
Arcutis Biotherapeutics Profit Margin (Quarterly) : 11.56% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.56% |
| March 31, 2026 | -10.72% |
| December 31, 2025 | 13.43% |
| September 30, 2025 | 7.47% |
| June 30, 2025 | -19.49% |
| March 31, 2025 | -38.06% |
| December 31, 2024 | -15.12% |
| September 30, 2024 | -92.81% |
| Date | Value |
|---|---|
| June 30, 2024 | -169.6% |
| March 31, 2024 | -71.38% |
| December 31, 2023 | -490.0% |
| September 30, 2023 | -117.5% |
| June 30, 2023 | -1.37K% |
| March 31, 2023 | -2.88K% |
| December 31, 2022 | -2.43K% |
| September 30, 2022 | -14.86K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Insmed, Inc. | -3.11% |
| Emergent BioSolutions, Inc. | -76.91% |
| Exelixis, Inc. | 33.73% |
| Vertex Pharmaceuticals, Inc. | 32.89% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 15.90% |
| Return on Assets | 6.77% |
| Return on Invested Capital | 9.74% |
| Gross Profit Margin (Quarterly) | 91.58% |
| Operating Margin (Quarterly) | 12.65% |
| Return on Net Operating Assets | 14.61% |